Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review
Abstract Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role is not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 is involved in the metabolism of triglyceride-rich lipoproteins by inhibiting the binding of very low density li...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-022-01703-5 |
| _version_ | 1811188189940940800 |
|---|---|
| author | Alexia Rouland David Masson Laurent Lagrost Bruno Vergès Thomas Gautier Benjamin Bouillet |
| author_facet | Alexia Rouland David Masson Laurent Lagrost Bruno Vergès Thomas Gautier Benjamin Bouillet |
| author_sort | Alexia Rouland |
| collection | DOAJ |
| description | Abstract Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role is not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 is involved in the metabolism of triglyceride-rich lipoproteins by inhibiting the binding of very low density lipoproteins (VLDL) to VLDL-receptor (VLDL-R), to low density lipoprotein receptor (LDL-R) and to LDL receptor related protein (LRP), by reducing the activity of lipoprotein lipase (LPL) and by stimulating VLDL production, all these effects leading to increase plasma triglycerides. ApoC1 takes also part in the metabolism of high density lipoproteins (HDL) by inhibiting Cholesterol Ester Transfer Protein (CETP). The functionality of apoC1 on CETP activity is impaired in diabetes that might account, at least in part, for the increased plasma CETP activity observed in patients with diabetes. Its different effects on lipoprotein metabolism with a possible role in the modulation of inflammation makes the net impact of apoC1 on cardiometabolic risk difficult to figure out and apoC1 might be considered as pro-atherogenic or anti-atherogenic depending on the overall metabolic context. Making the link between total plasma apoC1 levels and the risk of cardio-metabolic diseases is difficult due to the high exchangeability of this small protein whose biological effects might depend essentially on its association with VLDL or HDL. The role of apoC1 in humans is not entirely elucidated and further studies are needed to determine its precise role in lipid metabolism and its possible pleiotropic effects on inflammation and vascular wall biology. In this review, we will present data on apoC1 structure and distribution among lipoproteins, on the effects of apoC1 on VLDL metabolism and HDL metabolism and we will discuss the possible links between apoC1, atherosclerosis and diabetes. |
| first_indexed | 2024-04-11T14:16:23Z |
| format | Article |
| id | doaj.art-1165837690084f2e9dc2702566984802 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-04-11T14:16:23Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-1165837690084f2e9dc27025669848022022-12-22T04:19:23ZengBMCCardiovascular Diabetology1475-28402022-12-0121111810.1186/s12933-022-01703-5Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic reviewAlexia Rouland0David Masson1Laurent Lagrost2Bruno Vergès3Thomas Gautier4Benjamin Bouillet5Endocrinology and Diabetology Unit, University HospitalINSERM/University of Bourgogne Franche-Comté, LNC UMR1231INSERM/University of Bourgogne Franche-Comté, LNC UMR1231Endocrinology and Diabetology Unit, University HospitalINSERM/University of Bourgogne Franche-Comté, LNC UMR1231Endocrinology and Diabetology Unit, University HospitalAbstract Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role is not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 is involved in the metabolism of triglyceride-rich lipoproteins by inhibiting the binding of very low density lipoproteins (VLDL) to VLDL-receptor (VLDL-R), to low density lipoprotein receptor (LDL-R) and to LDL receptor related protein (LRP), by reducing the activity of lipoprotein lipase (LPL) and by stimulating VLDL production, all these effects leading to increase plasma triglycerides. ApoC1 takes also part in the metabolism of high density lipoproteins (HDL) by inhibiting Cholesterol Ester Transfer Protein (CETP). The functionality of apoC1 on CETP activity is impaired in diabetes that might account, at least in part, for the increased plasma CETP activity observed in patients with diabetes. Its different effects on lipoprotein metabolism with a possible role in the modulation of inflammation makes the net impact of apoC1 on cardiometabolic risk difficult to figure out and apoC1 might be considered as pro-atherogenic or anti-atherogenic depending on the overall metabolic context. Making the link between total plasma apoC1 levels and the risk of cardio-metabolic diseases is difficult due to the high exchangeability of this small protein whose biological effects might depend essentially on its association with VLDL or HDL. The role of apoC1 in humans is not entirely elucidated and further studies are needed to determine its precise role in lipid metabolism and its possible pleiotropic effects on inflammation and vascular wall biology. In this review, we will present data on apoC1 structure and distribution among lipoproteins, on the effects of apoC1 on VLDL metabolism and HDL metabolism and we will discuss the possible links between apoC1, atherosclerosis and diabetes.https://doi.org/10.1186/s12933-022-01703-5Apolipoprotein C1DiabetesAtherosclerosisLipoprotein metabolismTriglyceride-rich lipoproteinsHigh density lipoproteins |
| spellingShingle | Alexia Rouland David Masson Laurent Lagrost Bruno Vergès Thomas Gautier Benjamin Bouillet Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review Cardiovascular Diabetology Apolipoprotein C1 Diabetes Atherosclerosis Lipoprotein metabolism Triglyceride-rich lipoproteins High density lipoproteins |
| title | Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review |
| title_full | Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review |
| title_fullStr | Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review |
| title_full_unstemmed | Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review |
| title_short | Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review |
| title_sort | role of apolipoprotein c1 in lipoprotein metabolism atherosclerosis and diabetes a systematic review |
| topic | Apolipoprotein C1 Diabetes Atherosclerosis Lipoprotein metabolism Triglyceride-rich lipoproteins High density lipoproteins |
| url | https://doi.org/10.1186/s12933-022-01703-5 |
| work_keys_str_mv | AT alexiarouland roleofapolipoproteinc1inlipoproteinmetabolismatherosclerosisanddiabetesasystematicreview AT davidmasson roleofapolipoproteinc1inlipoproteinmetabolismatherosclerosisanddiabetesasystematicreview AT laurentlagrost roleofapolipoproteinc1inlipoproteinmetabolismatherosclerosisanddiabetesasystematicreview AT brunoverges roleofapolipoproteinc1inlipoproteinmetabolismatherosclerosisanddiabetesasystematicreview AT thomasgautier roleofapolipoproteinc1inlipoproteinmetabolismatherosclerosisanddiabetesasystematicreview AT benjaminbouillet roleofapolipoproteinc1inlipoproteinmetabolismatherosclerosisanddiabetesasystematicreview |